<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">34796716</PMID><DateRevised><Year>2021</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0001-723X</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2021</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Acta virologica</Title><ISOAbbreviation>Acta Virol</ISOAbbreviation></Journal><ArticleTitle>Seroprevalence of SARS-CoV-2 IgG antibodies in the staff of the Slovak Academy of Sciences in response to COVID-19 and/or vaccination: situation in August 2021.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4149/av_2021_407</ELocationID><Abstract><AbstractText>Cross-sectional seroprevalence study of SARS-CoV-2 IgG antibodies was accomplished in the Slovak Academy of Sciences to inform authorities of research institutions about the situation at their workplaces, to assess the risk of next exposure to SARS-CoV-2, and to guide decisions on institutional measures sustaining essential research in evolving epidemic situation. Study participants provided informed consent, anamnestic information, and self-collected dry blood spot samples that were analyzed by ELISA for SARS-CoV-2 S protein-specific IgG antibodies. Relative antibody levels detected in 1928 subjects showed seroprevalence of 84.13% and led to the following main findings consistent with the current knowledge: (1) mRNA-based vaccines induce better humoral response compared to adenovirus vaccines, (2) antibody levels reflect severity of COVID-19 symptoms, (3) post-COVID vaccination results in marked elevation of IgG levels particularly in asymptomatic and mild cases, (4) antibody levels decrease with increasing time elapsed from vaccination or COVID-19. In addition, data sorting to distinct research institutes and their clustering to three principal scientific sections of the Slovak Academy of Sciences revealed marked differences in seroprevalence, and allowed to identify workplaces with relatively high seropositivity and response rate that can potentially provide a safer working environment than those, where seroprevalence was low or unknown due to low participation. Thus, findings of this study can have direct implications on management decisions during the next pandemic development, with the necessity to keep in mind the phenomenon of time-dependent immunity waning and current spread of more contagious Delta variant of SARS-CoV-2. Keywords: SARS-CoV-2 coronavirus; COVID-19; spike protein; seroprevalence; antibodies; vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kajanova</LastName><ForeName>Ivana</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Lukacikova</LastName><ForeName>Lubomira</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Jelenska</LastName><ForeName>Lenka</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Grossmannova</LastName><ForeName>Katarina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Radikova</LastName><ForeName>Zofia</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Vlcek</LastName><ForeName>Miroslav</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Klempa</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kollar</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bodova</LastName><ForeName>Katarina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kopacek</LastName><ForeName>Juraj</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pastorekova</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Slovakia</Country><MedlineTA>Acta Virol</MedlineTA><NlmUniqueID>0370401</NlmUniqueID><ISSNLinking>0001-723X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>8</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34796716</ArticleId><ArticleId IdType="doi">10.4149/av_2021_407</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>